
BioSenic halts ALLOB development
ALLOB was developed before the US$40.8m majority buyout of Bone Therapeutics by French Medsenic SAS last October. Before the reverse merger, in...

Alnylam in US$2.8bn biobucks deal with Roche
The deal, which could fetch Alnylam Pharmaceuticals Inc up to US$2.8bn if all milestones are met and marketing approval is granted, clearly marks Big...

Mithra Pharmaceuticals SA in €17m licencing deal
Donesta is the first Estetrol-based hormone substitution therapy for the relief of menopausal vasomotor symptoms (VMS). Under a licencing deal with...

Lilly presents impressing results for Alzheimer's drug donanemab
Donanemab is the second antibody, after Eisai’s/Biogen’s accelarated approved lecanemab, that can slow the progression of dementia in early-stage...

Pairwise and Bayer collaborate to CRISPR short-stem maize
Following Leaps by Bayer's co-investment in a US$90m Series B financing in Pairwise Plants Services Inc. in 2021,German seed giant Bayer AG has...

Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...